Drawing for OTRERA MEDICAL

USPTO serial 98063859

OTRERA MEDICAL

Reviewed by CopyMark Law Group

Status 733Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
BONEN-CLARK, HOPE MICHELLE
Law office
TMO LAW OFFICE 110

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 733: Status 733 means the fourth six-month extension was granted. Only one extension typically remains before you must file a Statement of Use or risk abandonment.

Need help with OTRERA MEDICAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*

Plus Government fees of $300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joshua S. Jarvis, Esq.

Joshua S. Jarvis, Esq. Foley Hoag LLP155 Seaport BoulevardSeaport WestBoston, MA 02210-2600

Goods and services

ClassDescriptionStatusFirst use
005Medication for the treatment of sexual dysfunctionACTIVE—
042Scientific research; Scientific research and development; Scientific investigations for medical purposes; Medical and scientific research in the field of treatment of sexual dysfunction, sexual organs-related disorders, drug delivery to sexual organs, discovery and development of medications for the treatment of sexual dysfunctions, conducting clinical trials for others to determine efficacy of treatments of sexual dysfunctions; Scientific research for medical purposes in the field of female sexual dysfunction, sexual organs-related disorders, drug delivery to sexual organs, discovery and development of medications for the treatment of sexual dysfunctions; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Medical researchACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 30, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 29, 2026EX4GSOU EXTENSION 4 GRANTED—
Oct 29, 2026EXT4SOU EXTENSION 4 FILED—
Oct 29, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 7, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 6, 2026EX3GSOU EXTENSION 3 GRANTED—
May 6, 2026EXT3SOU EXTENSION 3 FILED—
May 6, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 30, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 29, 2025EX2GSOU EXTENSION 2 GRANTED—
Oct 29, 2025EXT2SOU EXTENSION 2 FILED—
Oct 29, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 8, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 8, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 8, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 8, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 8, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 13, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 12, 2025EX1GSOU EXTENSION 1 GRANTED—
May 12, 2025EXT1SOU EXTENSION 1 FILED—
May 12, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 12, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 17, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 17, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 28, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 12, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 12, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Aug 12, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 12, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 12, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 2, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 2, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 2, 2024ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jun 10, 2024GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jun 10, 2024GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 10, 2024CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 1, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 1, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 1, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 27, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 13, 2024DOCKASSIGNED TO EXAMINER—
Jul 31, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 1, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance